Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shake Fanning, Jürg Zimmermann, Nicholas B. Lydon

Research output: Contribution to journalArticle

2879 Citations (Scopus)

Abstract

The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

Original languageEnglish (US)
Pages (from-to)561-566
Number of pages6
JournalNature Medicine
Volume2
Issue number5
StatePublished - 1996

Fingerprint

bcr-abl Fusion Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Tumors
Assays
Bone
Blood
Cells
abl Genes
Growth
Leukemia
Bone Marrow
Cell Proliferation
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Druker, B., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., ... Lydon, N. B. (1996). Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nature Medicine, 2(5), 561-566.

Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. / Druker, Brian; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shake; Zimmermann, Jürg; Lydon, Nicholas B.

In: Nature Medicine, Vol. 2, No. 5, 1996, p. 561-566.

Research output: Contribution to journalArticle

Druker, B, Tamura, S, Buchdunger, E, Ohno, S, Segal, GM, Fanning, S, Zimmermann, J & Lydon, NB 1996, 'Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells', Nature Medicine, vol. 2, no. 5, pp. 561-566.
Druker B, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nature Medicine. 1996;2(5):561-566.
Druker, Brian ; Tamura, Shu ; Buchdunger, Elisabeth ; Ohno, Sayuri ; Segal, Gerald M. ; Fanning, Shake ; Zimmermann, Jürg ; Lydon, Nicholas B. / Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. In: Nature Medicine. 1996 ; Vol. 2, No. 5. pp. 561-566.
@article{e19f67ef5a0e48888efb542cbac3d600,
title = "Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells",
abstract = "The bcr-abl oncogene, present in 95{\%} of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98{\%} decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.",
author = "Brian Druker and Shu Tamura and Elisabeth Buchdunger and Sayuri Ohno and Segal, {Gerald M.} and Shake Fanning and J{\"u}rg Zimmermann and Lydon, {Nicholas B.}",
year = "1996",
language = "English (US)",
volume = "2",
pages = "561--566",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

AU - Druker, Brian

AU - Tamura, Shu

AU - Buchdunger, Elisabeth

AU - Ohno, Sayuri

AU - Segal, Gerald M.

AU - Fanning, Shake

AU - Zimmermann, Jürg

AU - Lydon, Nicholas B.

PY - 1996

Y1 - 1996

N2 - The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

AB - The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

UR - http://www.scopus.com/inward/record.url?scp=0029947186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029947186&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 561

EP - 566

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -